Tema Etfs LLC Reduces Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Tema Etfs LLC cut its stake in Arrowhead Pharmaceuticals by 63.7% in Q4, selling 20,253 shares and leaving it with 11,542 shares valued at $766,000.
• Company insiders sold a total of 99,657 shares worth $6.3 million last quarter (including COO Patrick O'Brien), leaving insiders with 3.60% ownership.
• Analysts have lifted targets and ratings recently, leaving the stock with a consensus rating of "Moderate Buy" and a consensus price target of $81.67 (several firms raised targets, e.g., Piper Sandler $110, Morgan Stanley $81).

Tema Etfs LLC cut its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 63.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,542 shares of the biotechnology company's stock after selling 20,253 shares during the period. Tema Etfs LLC's holdings in Arrowhead Pharmaceuticals were worth $766,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ARWR. iSAM Funds UK Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth about $29,000. Salomon & Ludwin LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $34,000. Federated Hermes Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $52,000. Smartleaf Asset Management LLC grew its stake in Arrowhead Pharmaceuticals by 2,186.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,618 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in Arrowhead Pharmaceuticals by 883.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock worth $66,000 after buying an additional 3,763 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ARWR shares. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 7th. Piper Sandler restated an "overweight" rating and set a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Bank of America lifted their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a "buy" rating in a report on Tuesday, December 9th. Chardan Capital increased their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a "buy" rating in a research note on Wednesday, January 7th. Finally, HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $81.67.

Insider Activity at Arrowhead Pharmaceuticals

In other news, COO Patrick O'brien sold 49,493 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer directly owned 474,908 shares of the company's stock, valued at $29,971,443.88. This trade represents a 9.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James C. Hamilton sold 40,164 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the transaction, the insider directly owned 171,958 shares in the company, valued at $10,852,269.38. This represents a 18.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 99,657 shares of company stock worth $6,300,153 in the last quarter. 3.60% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Stock Down 3.0%

ARWR stock opened at $61.03 on Friday. The stock has a market capitalization of $8.55 billion, a PE ratio of 39.89 and a beta of 1.26. The company has a fifty day moving average of $62.43 and a 200-day moving average of $54.33. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company's revenue was up 10461.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.39) earnings per share. As a group, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.